@article{fdi:010075145,
  title = {{A}nalysis of the clinical antibacterial and antituberculosis pipeline},
  author = {{T}heuretzbacher, {U}. and {G}ottwalt, {S}. and {B}eyer, {P}. and {B}utler, {M}. and {C}zaplewski, {L}. and {L}ienhardt, {C}hristian and {M}oja, {L}. and {P}aul, {M}. and {P}aulin, {S}. and {R}ex, {J}. {H}. and {S}ilver, {L}. {L}. and {S}pigelman, {M}. and {T}hwaites, {G}. {E}. and {P}accaud, {J}. {P}. and {H}arbarth, {S}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}his analysis of the global clinical antibacterial pipeline was done in support of the {G}lobal {A}ction {P}lan on {A}ntimicrobial {R}esistance. {T}he study analysed to what extent antibacterial and antimycobacterial drugs for systemic human use as well as oral non-systemic antibacterial drugs for {C}lostridium difficile infections were active against pathogens included in the {WHO} priority pathogen list and their innovativeness measured by their absence of cross-resistance (new class, target, mode of action). {A}s of {J}uly 1, 2018, 30 new chemical entity ({NCE}) antibacterial drugs, ten biologics, ten {NCE}s against {M}ycobacterium tuberculosis, and four {NCE}s against {C} difficile were identified. {O}f the 30 {NCE}s, 11 are expected to have some activity against at least one critical priority pathogen expressing carbapenem resistance. {T}he clinical pipeline is dominated by derivatives of established classes and most development candidates display limited innovation. {N}ew antibacterial drugs without pre-existing cross-resistance are under-represented and are urgently needed, especially for geographical regions with high resistance rates among {G}ram-negative bacteria and {M} tuberculosis.},
  keywords = {{MONDE}},
  booktitle = {},
  journal = {{L}ancet {I}nfectious {D}iseases},
  volume = {19},
  numero = {2},
  pages = {{E}40--{E}50},
  ISSN = {1473-3099},
  year = {2019},
  DOI = {10.1016/s1473-3099(18)30513-9},
  URL = {https://www.documentation.ird.fr/hor/fdi:010075145},
}